Suprefact (buserelin acetate) / Sanofi - LARVOL DELTA

Superovulation with eCG alone or combined with the GnRH analogue buserelin improves transferable embryo production in weaned sows without affecting day 6 embryo morphological, cellular, and transcriptomic parameters. (PubMed, Anim Reprod Sci) - "In conclusion, both hCG-free treatments increased embryo production in weaned sows without adversely affecting the Day-6 blastocyst quality parameters assessed, whereas the addition of buserelin further improved embryo-stage synchrony at collection. Overall, both protocols represent practical hCG-free strategies for in vivo porcine embryo production under commercial conditions."

Journal • CNS Disorders • Developmental Disorders • Psychiatry

Integrated hydrophobic modification and membrane interaction studies for enhanced delivery and selectivity of peptide therapeutics | Poster Board #1217 (ACS-Fall 2026) - "Buserelin (BUS), a clinically used agent for advanced prostate cancer, is limited by systemic side effects, motivating strategies to enhance its cellular uptake and efficacy...Furthermore, lipid-to-peptide ratios critically influenced selectivity, enabling PEN insertion into cancer-mimicking membranes while remaining surface-associated on healthy membranes. Together, these findings establish a design framework in which hydrophobic modification enhances intracellular delivery, while membrane composition and peptide–lipid balance govern selectivity, providing guiding principles for the development of safer and more effective peptide therapeutics."

Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - P3 | N=2753 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Dec 2033 ➔ Dec 2038

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Nov 2026 ➔ Nov 2031

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Optimizing ovulation synchronization in Holstein heifers: implementing a half-dose GnRH analogue (Buserelin Acetate) in a nanofabricated form within the ovsynch protocol to enhance the ovarian activity and reproductive performance outcomes. (PubMed, Front Vet Sci) - "Overall, the nano-GnRH-BA formulation within the OVS protocol resulted in a 50% reduction without compromising fertility, while also improving ovarian function and reducing PL in dairy heifers. This approach may represent a promising alternative to conventional synchronization strategies."

Journal • Inflammatory Arthritis

Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis. (PubMed, J Mol Histol) - "In conclusion, vitamin D₃ may have contributed to the regression of endometrial implants, possibly through mechanisms involving apoptotic pathways. Further studies are needed to clarify its role and to evaluate its potential clinical relevance."

IO biomarker • Journal • Preclinical • Endometriosis • Gynecology • Women's Health • BAX • BCL2

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. (PubMed, Analyst) - "The method was successfully applied to samples containing sub-ng levels of ibutamoren, confirming that the analytical procedure presented in this study is fit for purpose within the doping-control framework. At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma, whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum. In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs."

Journal

Effect of buserelin acetate at artificial insemination on pregnancy per AI in dairy cows inseminated with sexed semen. (PubMed, Braz J Vet Med) - "All animals were subjected to a standard ovulation-synchronization protocol, with AI performed 48 h after removing the progesterone device. The subgroup findings should be cautiously interpreted as the study was not specifically designed or powered for these comparisons. Further studies with relatively large populations are warranted to confirm these potential associations."

Journal

Effect of recombinant human follicle-stimulating hormone or equine chorionic gonadotropin on the ovarian response in guinea pig. (PubMed, Vet Res Commun) - "S1 involved oral administration of 0.4 mg/day altrenogest for 10 days, 0.0657 mg cloprostenol sodium intramuscularly on day 7, and 0.0013 mg buserelin acetate intramuscularly on day 10...The number of normal embryos recovered was similar between the S2-eCG and S2-r-hFSH/r-hLH groups. These findings suggest that applying the S2-eCG or S2-r-hFSH/r-hLH protocol in female guinea pigs increases the number of embryos recovered."

Journal

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis. (PubMed, J Coll Physicians Surg Pak) - "The cumulative probability ranking results showed that, for improving clinical pregnancy rate (CPR), leuprorelin (97.8%) ranked highest, followed by cetrorelix (70.7%), triptorelin (47.9%), buserelin (18.2%), and ganirelix (15.3%). For patients with the primary goal of improving CPR or LBR, leuprorelin is the more appropriate choice. Key Words: Polycystic ovary syndrome, Infertility, GnRH agonist, GnRH antagonist, Assisted reproduction."

Clinical • Journal • Retrospective data • Infertility • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders

Intravaginal GnRH analogues in rabbits: Fertirelin as the most effective option for ovulation induction. (PubMed, Theriogenology) - "This study evaluated three GnRH analogues (fertirelin, buserelin, and deslorelin) administered intravaginally in New Zealand White rabbits, assessing on ovulation induction, reproductive performance, and the minimum effective concentration...Neither analogue nor physiological status influenced total or live litter size. The stable performance of fertirelin irrespective of physiological condition supports its superior receptor affinity, making it a promising candidate for welfare-oriented intravaginal AI protocols in rabbits."

Journal • Preclinical

Changing the route of GnRH administration according to the initial cyclic phase of the Ovsynch protocol may optimize reproductive outcomes in dairy cows. (PubMed, BMC Vet Res) - "Consequently, although changing the GnRH analogue and administration route did not significantly affect overall fertility outcomes, the findings suggest a possible phase-dependent relationship between administration route and pregnancy outcome. However, this trend requires confirmation in further studies."

Journal

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Active, not recruiting | Sponsor: NRG Oncology | Recruiting ➔ Active, not recruiting

Enrollment closed • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

The ovulation trigger method affects gonadotropin concentrations and gonadotropin receptor expression during final oocyte maturation in women. (PubMed, Front Endocrinol (Lausanne)) - "Each participant contributed one follicle aspirated at T = 0,12,17 or 32h after trigger administration (0.5 mg GnRHa (buserelin) or 6,500 IU hCG) and a second follicle aspirated at oocyte pickup (T = 36h)...This may explain reports of slightly higher MII rates using the GnRHa trigger. These findings highlight the importance of temporal receptor dynamics in optimizing final oocyte maturation and support the use of GnRHa as a stand-alone trigger in freeze-all antagonist cycles and in combination with hCG (i.e., dual triggering) in fresh cycles to optimize oocyte maturation."

Journal

Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols. (PubMed, Theriogenology) - "On D0, cows received one intravaginal P4 device and estradiol benzoate (EB; Control) or buserelin acetate (GnRH/EC and 2GnRH). 2). In conclusion, removal of estradiol in ovulation synchronization protocols resulted in lower fertility relative to E2-based controls."

Journal

Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study. (PubMed, J Endocrinol Invest) - "The impairment of MCRI, which contributes to the hyperinsulinemia typical of PCOS, significantly improved after treatment with metformin. This effect was only partially explained by the reduction of BMI, whereas changes in insulin sensitivity did not show a mediation effect in this phenomenon, suggesting that other metformin-induced mechanisms are involved."

Journal • Polycystic Ovary Syndrome

Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use. (PubMed, F S Rep) - "The subjects were categorized into the following two groups according to the type of oocyte maturation trigger used: GnRHa group (buserelin [600 μg] nasal spray) and hCG group (hCG [3,000-10,000 IU] or choriogonadotropin alfa [250 μg] subcutaneously)...Although the MII ratio per oocyte did not show significant difference with the interval duration, the blastocyst formation rate and total number of blastocysts were markedly higher when the interval was longer than 36.5 hours in the GnRHa group. The optimal interval varies between the GnRHa trigger and the hCG trigger, with the hCG trigger associated with a shorter interval for obtaining the maximum number of MII oocytes than the GnRHa trigger."

Journal • Preclinical • Gynecology

Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates. (PubMed, Theriogenology) - "A total of 656 heifers underwent a first fixed-time artificial insemination (FTAI; designated as D0) and received a reused intravaginal progesterone (P4; 1 g) device on D22. The GnRH + EB group achieved a superior pregnancy rate at R22 (EB = 40.8 % vs. GnRH + EB = 56.0 %; P = 0.008) and a higher cumulative pregnancy rate (EB = 68.4 % vs. GnRH + EB = 79.2 %; P = 0.01). In conclusion, the administration of 10 μg of buserelin acetate combined with 1 mg of EB at the beginning of the R22 protocol improved conception rates in Bos taurus beef heifers."

Journal

Estradiol esters are dispensable in progesterone-based TAI protocols for Bos taurus suckling beef cows. (PubMed, Anim Reprod Sci) - "Also, on D0, cows in the Control group received 2 mg of estradiol benzoate IM and cows in the GnRH/GnRH and GnRH/EC groups received 20 µg of buserelin acetate IM. No difference was observed in the estrus rate before TAI (D9; 72.1, 62.4 and 67.9 %; P = 0.22) or in the pregnancy rate (56.9, 53.1 and 53.6 %; P = 0.77) for control (n = 153), GnRH/EC (n = 147) and GnRH/GnRH (n = 155), respectively. In conclusion, estradiol replacement by GnRH in TAI protocols does not affect LF diameter, estrus expression and pregnancy rate in suckling Bos taurus beef cows."

Journal

Pharmacokinetic Evaluation of Buserelin Acetate (Receptal) in Gilts. (PubMed, J Vet Pharmacol Ther) - "The clearance rate (CL) was 0.20 ± 0.03 L/h/kg, and the apparent volume of distribution (Vd) was 0.13 ± 0.05 L/kg. These results suggest that buserelin acetate from Receptal is rapidly metabolized and eliminated in gilts, emphasizing the need for precise timing of administration to maintain effective drug concentrations."

Journal • PK/PD data

Hormone responses to buserelin in polycystic ovary syndrome and in eumenorrheic women with hyperandrogenism/hyperandrogenemia, and the relationship of these responses with insulin resistance. (PubMed, J Clin Transl Endocrinol) - "However, IR presence impacted on more parameters in PCOS than EuHyperA. Given the known ovary sparing by IR in PCOS, it appears that IR exacerbates androgen production of PCOS women more markedly than EuHyperA women."

Journal • Polycystic Ovary Syndrome

RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - P3 | N=1538 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed

Trial completion • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Estradiol treatment and double dose of GnRH for resynchronization protocols and timed artificial insemination in lactating dairy cows. (PubMed, Theriogenology) - "The aim of this study was to compare pregnancy per AI (P/AI) in resynchronization (Resynch) protocols using different hormonal combinations (estradiol benzoate [EB], a double dose of GnRH, or EB with a double dose of GnRH) administered on the day of progesterone (P4) device insertion...The secondary objective was to compare P/AI in cows treated with two different GnRH agonists (gonadorelin acetate or buserelin acetate) on the day of P4 device insertion...In conclusion, the combined administration of EB and a double dose of GnRH does not improve P/AI compared with the administration of either hormone alone. Furthermore, both agonists produced comparable P/AI, confirming that they are equally effective when administered during P4 device insertion."

Journal

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - P3 | N=239 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed | Trial completion date: Jun 2029 ➔ Sep 2025

Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Effect of EC-GnRH34 timed AI protocol on ovulation synchrony and fertility in crossbred Girolando dairy cows. (PubMed, Trop Anim Health Prod) - "At the IPD removal, all cows were treated with 1 mg i.m estradiol cypionate (EC), and then allocated into two groups to receive either 2.5 mL of saline solution (EC-Control, n = 111) or 10.5 μg i.m. buserelin acetate (GnRH analogue) 34 h after IPD removal (EC-GnRH34, n = 115). In conclusion, the present study demonstrated that the ovulation synchrony is optimized with the use of GnRH 34 h after IPD removal. Fertility to the TAI protocol, however, was not significantly improved in comparison with cows treated with a single ovulation inducer, EC."

Journal